RESEARKA

This synthesis aims to address these gaps by providing a structured, cross-domain evaluation of rapamycin effects across the available evidence base. Across 36 curated reference papers, the evidence shows a context-dependent profile: positive signals appear in longevity and functional endpoints, negative signals emerge in specific safety and comorbidity contexts, and null findings dominate in several outcome categories. The synthesis identifies cross-study disagreements across outcome classes, reflecting fundamental disagreements about whether rapamycin effects are beneficial, harmful, or neutral depending on the population, dose, duration, and endpoint studied. By separating mechanistic evidence from clinical trial evidence, and by weighting each finding according to study design, directness, and effect direction, this work seeks to move beyond narrative summaries toward an actionable evidence architecture. The clinical-versus-mechanistic separation is particularly important because the tension between preclinical promise and human trial results is a recurring source of confusion in the field: preclinical studies consistently show rapamycin effects on lifespan and healthspan markers, while human trials report mixed or null results on functional endpoints. This synthesis will also examine the dose-response question, the duration-of-treatment question, and the population-specificity question with the aim of identifying boundary conditions under which rapamycin effects may be most likely to translate into clinical benefit. The rapamycin effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. By mapping these tensions explicitly and identifying the highest-priority evidence gaps, this synthesis aims to inform the design of future trials and to clarify the conditions under which rapamycin effects might move from promising preclinical biology to validated clinical geroprotection.

Citation Support

• source_1 Mandrioli 2023
• source_2 Lin 2022
• source_3 Moel 2025
• source_4 Gkioni 2025
• source_5 Zhou 2024